28 F. Supp. 3d 920
D. Minn.2014Background
- Plaintiff Candice Kruszka developed osteonecrosis of the jaw (ONJ/BIONJ) after treatment for multiple myeloma with Novartis’s bisphosphonate Aredia; plaintiffs assert Aredia caused her ONJ.
- The court previously issued a May 19, 2014 order resolving summary judgment and admitting certain retained experts; additional Daubert and in limine challenges remained for numerous proposed experts.
- Parties filed motions to exclude or limit testimony from several experts (Drs. Huff, Baur, Arrowsmith, Feigal, Parisian, Vogel and others) and plaintiffs sought unsealing of a sealed MDL document declaration and exhibits.
- The court applied Daubert and Rule 702 gatekeeping principles, distinguishing expertise on FDA/regulatory matters from medical causation and corporate state-of-mind opinions.
- The court granted, denied, or limited expert testimony in part: some experts were permitted to testify within their specialties (oncology or FDA process) but barred from opinions outside their expertise (dental diagnosis, corporate intent, legal conclusions, causal mechanisms stated as definitive).
- The court ordered selective unsealing: exhibits already admitted at prior trials are public; remaining Germany exhibits remain sealed and will be addressed case-by-case at trial.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Admissibility/scope of Dr. Carol Huff (oncologist) | Huff is unqualified for specific-causation/dental/ONJ diagnosis and quality-of-life risk–benefit opinions | Novartis: Huff is qualified on myeloma treatment, Aredia effects, and quality‑of‑life impacts | Granted in part/Denied in part — Huff may testify on myeloma treatment, Aredia effects, and QoL when grounded in oncology expertise; barred from dental/ONJ diagnosis and untimely declaration material |
| Admissibility/scope of Dr. Dale Baur (oral surgeon) | Baur lacks oncology prescribing experience to opine on risk–benefit, QoL, or adequacy of warnings | Novartis: Baur qualified on ONJ and related causation as oral/maxillofacial surgeon | Granted in part — Baur may address ONJ causation and dental issues but is excluded from testifying on overall bisphosphonate risk–benefit, QoL improvements, or adequacy/timeliness of warnings |
| Experts testifying about FDA compliance or Novartis state of mind (Arrowsmith, Feigal) | Exclude opinions about FDA/Novartis state of mind and regulatory conclusions | Novartis: Experts can explain FDA processes and reasonableness of company conduct vis‑à‑vis FDA | Granted in part/Denied in part — Experts may testify about FDA regulatory framework and reasonableness of Novartis’s compliance; may not opine on intent, motives, or corporate/FDA "state of mind" or legal conclusions |
| Admissibility/scope of Dr. Suzanne Parisian (FDA/regulatory) | Parisian should be excluded or limited; cannot opine on causation, corporate intent, industry practices outside FDA | Novartis: Parisian is qualified on FDA processes and Novartis compliance | Granted in part/Denied in part — Parisian may testify on FDA regulations/procedure and Novartis’s compliance with them from FDA perspective; excluded from medical causation, regulatory "causal association," corporate intent, industry‑practice opinions, ghostwriting, and legal conclusions |
| Admissibility/scope of Dr. James Vogel (oncologist) — multiple topics | Novartis challenges corporate conduct opinions, pre‑treatment dental screening foundation, ONJ incidence, alternative dosing, and biological mechanism | Plaintiffs: Vogel qualified by oncology experience and literature review to opine on these issues | Granted in part/Denied in part — Vogel may testify on medical interpretation of Novartis documents (not corporate intent), pre‑treatment dental screening (subject to foundation), incidence (opinion that ONJ ≥5%), dosing/duration, and plausible biological mechanisms (as non‑definitive) |
| Unsealing Germany declaration/exhibits | Plaintiffs: most exhibits are old/public interest supports unsealing | Novartis: competitive sensitivity and MDL confidentiality order justify sealing | Granted in part/Denied in part — Exhibits admitted at prior trials are unsealed; remaining exhibits remain sealed and addressed at trial if/when used |
Key Cases Cited
- Daubert v. Merrell Dow Pharm., 509 U.S. 579 (established trial‑court gatekeeper role for scientific expert testimony)
- Kumho Tire Co. v. Carmichael, 526 U.S. 137 (Daubert reliability inquiry applies to all expert testimony)
- Lauzon v. Senco Prods., 270 F.3d 681 (8th Cir.) (Rule 702 prerequisites summarized)
- Wheeling Pittsburgh Steel Corp. v. Beelman River Terminals, 254 F.3d 706 (8th Cir.) (trial judge determines whether expert can assist jurors)
- Bonner v. ISP Techs., 259 F.3d 924 (8th Cir.) (factual basis often goes to credibility not admissibility)
- Gen. Elec. Co. v. Joiner, 522 U.S. 136 (district court may exclude opinions with analytical gap)
- Deutsch v. Novartis Pharm. Corp., 768 F. Supp. 2d 420 (E.D.N.Y.) (limits on expert testimony about corporate intent; admissibility of regulatory/causation testimony by non‑industry experts)
- In re Baycol Prods. Litig., 532 F. Supp. 2d 1029 (D. Minn.) (corporate intent is jury question; limits on expert testimony about intent)